Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 203-210

  Chittawatanarat, Kaweesak ^a   Jaipakdee, Wuttipong ^a   Chotirosniramit, Narain ^a   Chandacham, Kamtone ^a   Jirapongcharoenlap, Tidarat ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Acinetobacter baumannii; Device related incidence rate; Drug resistant organism; Surgical intensive care unit; Ventilator associated pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; LEVOFLOXACIN; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SURVEILLANCE PROGRAM; ENDOTRACHEAL INTUBATION; EXTENSIVELY DRUG RESISTANCE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INFECTION SENSITIVITY; INJURY; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATOR; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PAN DRUG RESISTANCE; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SEPSIS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TERTIARY CARE CENTER; THAILAND; UNIVERSITY HOSPITAL; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84906258368     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S67267     Document Type: Article

References (28)

1. Chittawatanarat K, Jaikriengkrai K, Permpikul C, Thai Society of Critical Care Study group. Survey of respiratory support for intensive care patients in 10 Tertiary hospital of Thailand. J Med Assoc Thai. 2014;97(Suppl 1):S8-S14.
2. Wilke M, Grube R. Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist. 2013;7:1-7.
3. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
4. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81-S87.
5. Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Control. 2008;36(Suppl 4):S93-S100.
6. Minei JP, Nathens AB, West M, et al. Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core - standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. J Trauma. 2006;60(5):1106-1113.
7. Zygun DA, Zuege DJ, Boiteau PJ, et al. Ventilator-associated pneumonia in severe traumatic brain injury. Neurocrit Care. 2006;5(2):108-114.
8. Hamilton LA, Christopher Wood G, Magnotti LJ, et al. Treatment of methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia with high-dose vancomycin or linezolid. J Trauma Acute Care Surg. 2012;72(6):1478-1483.
9. Apisarnthanarak A, Buppunharun W, Tiengrim S, Sawanpanyalert P, Aswapokee N. An overview of antimicrobial susceptibility patterns for gram-negative bacteria from the National Antimicrobial Resistance Surveillance Thailand (NARST) program from 2000 to 2005. J Med Assoc Thai. 2009;92(Suppl 4):S91-S94.
10. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev. 2006;19(4):637-657.
11. Morris AJ, Tanner DC, Reller LB. Rejection criteria for endotracheal aspirates from adults. J Clin Microbiol. 1993;31(5):1027-1029.
12. Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995;108(6):1655-1662.
13. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281.
14. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-686.
15. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008;197(9):1226-1234.
16. McCrory R, Jones DS, Adair CG, Gorman SP. Pharmaceutical strategies to prevent ventilator-associated pneumonia. J Pharm Pharmacol. 2003;55(4):411-428.
17. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from Jan 1992 through Jun 2004, issued Oct 2004. Am J Infect Control. 2004;32(8):470-485.
18. Reechaipichitkul W, Phondongnok S, Bourpoern J, Chaimanee P. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Srinagarind Hospital, northeastern Thailand. Southeast Asian J Trop Med Public Health. 2013;44(3):490-502.
19. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.J Med Assoc Thai. 2010;93(Suppl 1):S126-S138.
20. Parker CM, Kutsogiannis J, Muscedere J, et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care. 2008;23(1):18-26.
21. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis. 2010;23(4):332-339.
22. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013;13(8):665-671.
23. Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Roisin R, Agusti-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest. 1988;93(2):318-324.
24. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 2001;27(2):355-362.
25. Mueller EW, Hanes SD, Croce MA, Wood GC, Boucher BA, Fabian TC. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma. 2005;58(1):94-101.
26. Caricato A, Montini L, Bello G, et al. Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients. Intensive Care Med. 2009;35(11):1964-1969.
27. Combes A, Figliolini C, Trouillet JL, et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest. 2002;121(5): 1618-1623.
28. Michetti CP, Aldaghlas T. Differences in management and mortality with a bronchoalveolar lavage-based diagnostic protocol for ventilator-associated pneumonia. J Trauma Acute Care Surg. 2012; 72(1):242-246.